Wikipedia -WSS

Wikipedia

author：explore 2025-09-29 22:37:22 - browse：65

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

focus

WSS

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Medicare coverage of Wegovy, once blocked, now looks possible

Male and female sex labels in research insufficient, scientists say

Male and female sex labels in research insufficient, scientists say

Readout Newsletter: CAR

hotspot

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

In Memoriam: Notable people who died in 2023

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Medical records are filled with copy

Does good food count as health care? Study aims to find out

Tori Bowie and the unacceptable rates of Black maternal death

NYU radiologists take on the challenge of expensive MRI machines

Psychedelics group wrestles with new pharma identity

NYU radiologists take on the challenge of expensive MRI machines

Wikipedia

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

FDA advisers back CAR

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

How many hemophilia patients actually want gene therapy?

HHS secretary Becerra pressed on Change HealthCare cyberattack

World's first CRISPR

knowledge

hotspot

focus

focus